SANA

Sana Biotechnology, Inc.
CAPPED RATING

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc. (SANA) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.6
EV / EBITDA -3.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -45.1%
Price Return 12M -50.3%
Catalyst Signal 0.00
Market Cap $605.3M
TTM Revenue N/A
Price / Sales N/A
ROE -79.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C- (2.0) D (1.3) D+ (1.6) C+ (2.6) C- (2.0)
2026-11-07 C+ (2.5) C- (1.9) D+ (1.8) C- (1.9) C+ (2.7) C (2.2)
2026-10-31 C+ (2.5) C- (1.9) D (1.2) C (2.2) C+ (2.7) C- (2.1)
2026-10-24 C+ (2.5) C- (1.9) D (1.2) D+ (1.8) C+ (2.6) C- (2.0)
2026-10-17 C+ (2.5) C- (1.9) D (1.2) C- (1.9) C+ (2.6) C- (2.0)
Page 1 of 4